© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 21, 1794,
November 3, 1999
© 1999 Oxford University Press
EDITORIALS |
Vitamin A Analogue for Breast Cancer Prevention: a Grade of F or Incomplete?
Correspondence to: Steven Piantadosi, M.D., Ph.D., Oncology Biostatistics, The Johns Hopkins Oncology Center, The Johns Hopkins University, School of Medicine, Baltimore, MD 21205-2013.
Many eyes will be drawn to the article reported in this issue of
the Journal by Veronesi et al. (1), who tested the effect of
the vitamin A analogue fenretinide on the prevention of second breast
malignancies in women with early breast cancer. Veronesi et al.
randomly assigned nearly 3000 women to receive either fenretinide
orally or no treatment (control group) for 5 years and followed them
for a
NOTES
REFERENCES
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
U. Veronesi, G. De Palo, E. Marubini, A. Costa, L. Mariani, F. Formelli, and A. Decensi Re: Vitamin A Analogue for Breast Cancer Prevention: a Grade of F or Incomplete? J Natl Cancer Inst, February 2, 2000; 92(3): 274 - 274. [Full Text] [PDF] |
||||
![]() |
F. L. Meyskens Jr. Re: Vitamin A Analogue for Breast Cancer Prevention: a Grade of F or Incomplete? J Natl Cancer Inst, February 2, 2000; 92(3): 274a - 274a. [Full Text] [PDF] |
||||
